Seong-Hwan Chang

Prof. Dr. Seong-Hwan Chang


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2009 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
SCSeong-Hwan Chang
Seong-Hwan Chang
HLHae-Won Lee
Hae-Won Lee
HKHae-Kyoung Kim
Hae-Kyoung Kim
SKSeong-Hyop Kim
Seong-Hyop Kim
DKDuk-Kyung Kim
Duk-Kyung Kim
Postlaparoscopic shoulder pain (PLSP) frequently follows laparoscopic surgery. In this placebo-controlled study, we evaluated the efficacy of two perioperative doses of pregabalin 300 mg 12 h apart for preventing and attenuating PLSP after laparoscopic cholecystectomy. The frequency and severity of PLSP, need for postoperative rescue analgesia, and side effect profiles were assessed for 48 h postoperatively. In both groups, the overall incidence of PLSP did not differ significantly, and the pain score for PLSP, time to first rescue analgesia, and cumulative ketorolac consumption were similar at each timepoint. However, the 2-h postoperative incidence of oversedation was higher with pregabalin.

19 September 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
SLSeung Eun Lee
Seung Eun Lee
SCSeong-Hwan Chang
Seong-Hwan Chang
WKWook Youn Kim
Wook Youn Kim
SLSo Dug Lim
So Dug Lim
WKWan Seop Kim
Wan Seop Kim
HHHye Seung Han
Hye Seung Han
Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma

29 March 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ANArulkumar Nagappan
Arulkumar Nagappan
WLWon Sup Lee
Won Sup Lee
JYJeong Won Yun
Jeong Won Yun
JLJing Nan Lu
Jing Nan Lu
SCSeong-Hwan Chang
Seong-Hwan Chang
SHSoon Chan Hong
Soon Chan Hong
Tetraarsenic hexoxide (As4O6) has been used in Korean folk medicines for the treatment of cancer, however its anti-cancer mechanisms remain obscured. Here, this study investigated the anti-cancer effect of As4O6 on SW620 human colon cancer cells. As4O6 has showed a dose-dependent inhibition of SW620 cells proliferation. As4O6 significantly increased the sub-G1 and G2/M phase population, and Annexin V-positive cells in a dose-dependent manner. G2/M arrest was concomitant with augment of p21 and reduction in cyclin B1, cell division cycle 2 (cdc 2) expressions. Nuclear condensation, cleaved nuclei and poly (adenosine diphosphate‑ribose) polymerase (PARP) activation were also observed in As4O6-treated SW620 cells. As4O6 induced depolarization of mitochondrial membrane potential (MMP, ΔΨm) but not reactive oxygen species (ROS) generation. Further, As4O6 increased death receptor 5 (DR5), not DR4 and suppressed the B‑cell lymphoma‑2 (Bcl-2) and X-linked inhibitor of apoptosis protein (XIAP) family proteins. As4O6 increased the formation of AVOs (lysosomes and autophagolysosomes) and promoted the conversion of microtubule-associated protein 1A/1B-light chain 3 (LC3)-I to LC3-II in a dose- and time- dependent manner. Interestingly, a specific phosphoinositide 3-kinase (PI3K)/Akt inhibitor (LY294002) augmented the As4O6 induced cell death; whereas p38 mitogen-activated protein kinases (p38 MAPK) inhibitor (SB203580) abrogated the cell death. Thus, the present study provides the first evidence that As4O6 induced G2/M arrest, apoptosis and autophagic cell death through PI3K/Akt and p38 MAPK pathways alteration in SW620 cells.

1 June 2003 in Hepatology
Verified
Journal Article
Closed access
PDF file
SCSeong-Hwan Chang
Seong-Hwan Chang
KSKyung Su Suh
Kyung Su Suh
NYNam-Joon Yi
Nam-Joon Yi
SCSeok Ho Choi
Seok Ho Choi
HLHoan Jong Lee
Hoan Jong Lee
KLKuhn Uk Lee
Kuhn Uk Lee
The shortage of donor organs occasionally mandates the use of hepatic allografts from anti–HBc (+) donors. HBIG and/or lamivudine are recommended for the prevention of de novo HBV infection in naive patients, but there are attendant problems, such as mutant strain emergence and high cost. Active immunization presents a better alternative than the use of HBIG or lamivudine, if it can be proven to be effective. Accordingly, we investigated the outcome of HBV vaccination in pediatric hepatic transplant recipients. Between July 1999 and October 2001, 19 pediatric recipients were administered HBV vaccinations after liver transplantation at Seoul National University Hospital. Nine patients received a graft from anti–HBc (+) donors and 10 from anti–HBc (-) donors. When steroid was withdrawn, recombinant HBV vaccine was administered. The median follow–up period after vaccination was 10.0 ± 5.2 months. Seventeen of the 19 patients showed a positive response to vaccination. In 9 patients who received grafts from anti–HBc (+) donors, 2 patients showed no response, 4 patients low response (peak HBsAb titer <1,000 IU/L), and 3 patients high response (peak HBsAb titer ≥1,000 IU/L). De novo HBV infection developed in 1 of 2 patients who showed no response to vaccination. In 10 patients who received grafts from anti–HBc (-) donors, 5 showed a low response and 5 a high response. In conclusion, HBV vaccination in pediatric patients after liver transplantation appeared to exhibit some effectiveness at protecting young children that received a graft from anti–HBc (+) donors from de novo HBV infection.

1 January 2011 in Korean Journal of Radiology
Verified
Journal Article
Open access
PDF file
ICIl Soo Chang
Il Soo Chang
HCHyun Keun Chee
Hyun Keun Chee
SPSang Woo Park
Sang Woo Park
IYIk Jin Yun
Ik Jin Yun
JHJae Joon Hwang
Jae Joon Hwang
HJHong Geun Jung
Hong Geun Jung
Chang IS, et al. Korean J Radiol. 2011 Mar-Apr;12(2):203-209. http://dx.doi.org/10.3348/kjr.2011.12.2.203

19 May 2006 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
CKCH David Kwon
CH David Kwon
KSKyung Su Suh
Kyung Su Suh
NYNam‐Joon Yi
Nam‐Joon Yi
SCSeong-Hwan Chang
Seong-Hwan Chang
YCYong Beom Cho
Yong Beom Cho
KLKuhn Uk Lee
Kuhn Uk Lee